Warning: The NCBI web site requires JavaScript to function. more...
Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant.
Watkins JD, Campbell GR, Halimi H, Loret EP.
Retrovirology. 2008 Sep 22;5:83.
Related citations
Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
Grégoire C, Péloponèse JM Jr, Esquieu D, Opi S, Campbell G, Solomiac M, Lebrun E, Lebreton J, Loret EP.
Biopolymers. 2001;62(6):324-35.
1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein.
Péloponèse JM Jr, Grégoire C, Opi S, Esquieu D, Sturgis J, Lebrun E, Meurs E, Collette Y, Olive D, Aubertin AM, Witvrow M, Pannecouque C, De Clercq E, Bailly C, Lebreton J, Loret EP.
C R Acad Sci III. 2000 Oct;323(10):883-94.
Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates.
Gregoire CJ, Loret EP.
J Biol Chem. 1996 Sep 13;271(37):22641-6.
HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy.
Shojania S, O'Neil JD.
J Biol Chem. 2006 Mar 31;281(13):8347-56. Epub 2006 Jan 19.
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.
Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP.
J Biol Chem. 2004 Nov 12;279(46):48197-204. Epub 2004 Aug 24.
Solid-state NMR data support a helix-loop-helix structural model for the N-terminal half of HIV-1 Rev in fibrillar form.
Blanco FJ, Hess S, Pannell LK, Rizzo NW, Tycko R.
J Mol Biol. 2001 Nov 2;313(4):845-59.
Sequence-specific resonance assignments of the 1H-NMR spectra of a synthetic, biologically active EIAV Tat protein.
Willbold D, Krüger U, Frank R, Rosin-Arbesfeld R, Gazit A, Yaniv A, Rösch P.
Biochemistry. 1993 Aug 24;32(33):8439-45.
Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states.
Hakansson S, Caffrey M.
Biochemistry. 2003 Aug 5;42(30):8999-9006.
UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.
Foucault M, Mayol K, Receveur-Bréchot V, Bussat MC, Klinguer-Hamour C, Verrier B, Beck A, Haser R, Gouet P, Guillon C.
Proteins. 2010 May 1;78(6):1441-56.
Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism.
Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U.
J Biol Chem. 2003 Oct 31;278(44):43188-201. Epub 2003 Jul 23.
The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth.
Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S, Reinhold D.
J Biol Chem. 1997 Nov 28;272(48):30283-8.
High yield expression and purification of HIV-1 Tat1-72 for structural studies.
Shojania S, Henry GD, Chen VC, Vo TN, Perreault H, O'Neil JD.
J Virol Methods. 2010 Mar;164(1-2):35-42. Epub 2009 Nov 24.
Complete 1H nuclear magnetic resonance assignments and structural characterization of a fusion protein of the alpha-amylase inhibitor tendamistat with the activation domain of the human immunodeficiency virus type 1 Tat protein.
Freund J, Vértesy L, Koller KP, Wolber V, Heintz D, Kalbitzer HR.
J Mol Biol. 1995 Jul 28;250(5):672-88.
Membrane-bound dynamic structure of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV TAT, from solid-state NMR.
Su Y, Waring AJ, Ruchala P, Hong M.
Biochemistry. 2010 Jul 27;49(29):6009-20.
Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
Campbell GR, Senkaali D, Watkins J, Esquieu D, Opi S, Yirrell DL, Kaleebu P, Loret EP.
Vaccine. 2007 Dec 5;25(50):8441-7. Epub 2007 Oct 22.
Tat peptide-calmodulin binding studies and bioinformatics of HIV-1 protein-calmodulin interactions.
McQueen P, Donald LJ, Vo TN, Nguyen DH, Griffiths H, Shojania S, Standing KG, O'Neil JD.
Proteins. 2011 Jul;79(7):2233-46. doi: 10.1002/prot.23048. Epub 2011 May 10.
Structural studies of the equine infectious anemia virus trans-activator protein.
Willbold D, Volkmann A, Metzger AU, Sticht H, Rosin-Arbesfeld R, Gazit A, Yaniv A, Frank RW, Rösch P.
Eur J Biochem. 1996 Aug 15;240(1):45-52.
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
Opi S, Péloponèse JM Jr, Esquieu D, Campbell G, de Mareuil J, Walburger A, Solomiac M, Grégoire C, Bouveret E, Yirrell DL, Loret EP.
J Biol Chem. 2002 Sep 27;277(39):35915-9. Epub 2002 Jun 21.
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
Campbell GR, Loret EP.
Retrovirology. 2009 May 25;6:50. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on